UCB SA (OTCMKTS:UCBJY) Short Interest Down 99.1% in August

UCB SA (OTCMKTS:UCBJY) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totalling 100 shares, a drop of 99.1% from the July 31st total of 11,100 shares. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 0.0 days.

UCB Trading Down 0.5 %

Shares of UCBJY opened at $90.05 on Thursday. The stock has a fifty day moving average price of $80.83 and a two-hundred day moving average price of $69.26. UCB has a 52-week low of $34.85 and a 52-week high of $90.60.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.